SGLT2抑制剂在非白蛋白尿性糖尿病肾病中的心肾事件
随访3年,倾向评分匹配后,SGLT2抑制剂与进展为大量白蛋白尿及全因死亡风险降低相关。
要点
- 在2型糖尿病合并非白蛋白尿性CKD患者中,SGLT2抑制剂使用与进展为大量白蛋白尿风险降低相关。
- 倾向评分匹配后,SGLT2抑制剂使用与全因死亡风险降低相关。
- 匹配前意向性治疗模型中,SGLT2抑制剂还与透析、MACE和AKI风险降低相关。
核心结论
- 在2型糖尿病合并非白蛋白尿性CKD患者中,使用SGLT2抑制剂与进展为大量白蛋白尿及全因死亡风险显著降低相关。
研究设计与样本
- 采用Cox比例风险模型分析SGLT2抑制剂使用与结局的风险关联,研究随访时间为3年。
主要发现
- 匹配前意向性治疗模型中,SGLT2抑制剂使用与透析风险降低相关(aHR 0.21;95%CI 0.10-0.44;P<0.001)。
- 匹配前意向性治疗模型中,SGLT2抑制剂使用与进展为大量白蛋白尿风险降低相关(aHR 0.86;95%CI 0.79-0.94;P=0.001)。
- 匹配前意向性治疗模型中,SGLT2抑制剂使用与MACE风险降低相关(aHR 0.85;95%CI 0.76-0.95;P=0.005)。
- 匹配前意向性治疗模型中,SGLT2抑制剂使用与AKI风险降低相关(aHR 0.68;95%CI 0.56-0.82;P<0.001)。
- 匹配前意向性治疗模型中,SGLT2抑制剂使用与全因死亡风险降低相关(aHR 0.63;95%CI 0.52-0.76;P<0.001)。
关键数值与推荐
- 倾向评分匹配后,SGLT2抑制剂使用与进展为大量白蛋白尿风险降低相关(aHR 0.84;95%CI 0.73-0.97;P=0.015)。
- 倾向评分匹配后,SGLT2抑制剂使用与全因死亡风险降低相关(aHR 0.40;95%CI 0.28-0.59;P<0.001)。
临床怎么用
- 对于2型糖尿病合并非白蛋白尿性CKD患者,可考虑使用SGLT2抑制剂以降低进展为大量白蛋白尿和全因死亡的风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Most patients with type 2 diabetes (T2D) and chronic kidney disease (CKD) do not exhibit albuminuria. However, data are limited regarding the potential benefits of sodium-glucose cotransporter-2 inhibitors (SGLT2is) in this subgroup. METHODS: We conducted a population-based cohort study between May 1, 2016, and December 31, 2021 using Taiwan's National Health Insurance (NHI) Research Database to examine the association between SGLT2is use and outcome in patients with T2D and nonalbuminuric CKD. Cox proportional hazard models were used to determine the risk of outcomes between the study and control groups. RESULTS: The study follow-up time was 3 years. In the prematched intention-to-treat (ITT) model, SGLT2is use was associated with lower risks of dialysis (adjusted hazard ratio [aHR]: 0.21; 95% confidence interval [CI]: 0.10-0.44; P < 0.001), progression to macroalbuminuria (aHR: 0.86; 95% CI: 0.79-0.94; P = 0.001), major adverse cardiovascular events (MACE) (aHR: 0.85; 95% CI: 0.76-0.95; P = 0.005), acute kidney injury (AKI) (aHR: 0.68; 95% CI: 0.56-0.82; P < 0.001), and all-cause mortality (aHR: 0.63; 95% CI: 0.52-0.76; P < 0.001) compared with no SGLT2is use. After propensity score matching, multivariable analyses showed that SGLT2is use was associated with a lower risk of progression to macroalbuminuria (aHR: 0.84; 95% CI: 0.73-0.97; P = 0.015), and all-cause mortality (aHR: 0.40; 95% CI: 0.28-0.59; P < 0.001) compared with not using SGLT2is. CONCLUSION: This nationwide cohort study showed that SGLT2is use was associated with a significantly lower risk of progression to macroalbuminuria, and all-cause mortality compared with nonuse in patients with T2D and nonalbuminuric CKD.
引用
- Yen FS, Chong K, Huang CW, et al. Sodium-Glucose Cotransporter-2 Inhibitors and Cardiorenal Events in Nonalbuminuric Kidney Disease. Kidney Int Rep. 2025. PMID: 41630897. doi:10.1016/j.ekir.2025.103756
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。